Revolution Medicines (RVMD) Depreciation & Amortization (CF) (2019 - 2026)

Revolution Medicines' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 37.5% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $8.0 million, a 29.03% increase from a year earlier, with the FY2025 full-year figure at $7.4 million, up 19.35% from the prior year.
• Depreciation & Amortization (CF) improved to $2.2 million in Q1 2026 per RVMD's latest filing, from $2.1 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $2.2 million in Q1 2026 and bottomed at $901000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $1.4 million (2024), against an average of $1.5 million.
• Biggest YoY gain for Depreciation & Amortization (CF) was 50.0% in 2025; the steepest drop was 6.25% in 2025.
• Year by year, Depreciation & Amortization (CF) stood at $1.2 million in 2022, then grew by 10.88% to $1.3 million in 2023, then rose by 7.28% to $1.4 million in 2024, then surged by 50.0% to $2.1 million in 2025, then gained by 4.76% to $2.2 million in 2026.
• Per Business Quant, the three latest RVMD Depreciation & Amortization (CF) figures stand at $2.2 million (Q1 2026), $2.1 million (Q4 2025), and $2.0 million (Q3 2025).